SG Americas Securities LLC Boosts Holdings in GeneDx Holdings Corp. $WGS

Key Points

• SG Americas Securities LLC boosted its stake in GeneDx by 937.3% in Q4, buying 57,090 shares to hold 63,181 shares (about 0.22% of the company) valued at $8,217,000.
• Insiders sold a total of 65,875 shares worth $5,280,990 in the last quarter (including sales by COO Bryan Dechairo and CFO Kevin Feeley), although insiders still own 29.60% of the stock.
• GeneDx slightly beat quarterly expectations (EPS $0.14 vs. $0.11 estimate; revenue $120.99M vs. $120.80M) and carries a consensus "Moderate Buy" rating with an average target price of $140.71 versus a current market price near $59.61 and a market cap of $1.75B.

SG Americas Securities LLC lifted its position in shares of GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 937.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 63,181 shares of the company's stock after purchasing an additional 57,090 shares during the period. SG Americas Securities LLC owned about 0.22% of GeneDx worth $8,217,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in WGS. Jones Financial Companies Lllp increased its stake in GeneDx by 664.3% during the 3rd quarter. Jones Financial Companies Lllp now owns 214 shares of the company's stock worth $25,000 after buying an additional 186 shares during the period. Quarry LP boosted its position in GeneDx by 248.8% in the 3rd quarter. Quarry LP now owns 293 shares of the company's stock valued at $32,000 after buying an additional 209 shares during the last quarter. Gordian Capital Singapore Pte Ltd acquired a new stake in shares of GeneDx during the third quarter valued at about $65,000. AlphaQuest LLC grew its stake in shares of GeneDx by 70.8% during the third quarter. AlphaQuest LLC now owns 1,303 shares of the company's stock valued at $140,000 after acquiring an additional 540 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its position in shares of GeneDx by 479.0% during the second quarter. Tower Research Capital LLC TRC now owns 1,818 shares of the company's stock worth $168,000 after acquiring an additional 1,504 shares during the last quarter. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

GeneDx Stock Performance

Shares of GeneDx stock opened at $59.61 on Tuesday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.34 and a current ratio of 2.46. GeneDx Holdings Corp. has a 1 year low of $55.17 and a 1 year high of $170.87. The firm's 50-day simple moving average is $84.57 and its 200-day simple moving average is $116.11. The firm has a market cap of $1.75 billion, a PE ratio of -79.48 and a beta of 2.03.

GeneDx (NASDAQ:WGS - Get Free Report) last announced its quarterly earnings data on Monday, February 23rd. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.03. GeneDx had a positive return on equity of 14.73% and a negative net margin of 4.92%.The firm had revenue of $120.99 million during the quarter, compared to analyst estimates of $120.80 million. Equities analysts forecast that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Insider Transactions at GeneDx

In other news, COO Bryan Dechairo sold 5,961 shares of the business's stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $85.70, for a total value of $510,857.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Kevin Feeley sold 6,187 shares of the firm's stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $78.61, for a total value of $486,360.07. Following the transaction, the chief financial officer owned 18,674 shares in the company, valued at $1,467,963.14. This trade represents a 24.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 65,875 shares of company stock worth $5,280,990 in the last quarter. Insiders own 29.60% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on WGS. Piper Sandler reiterated an "overweight" rating and issued a $130.00 price target (down from $160.00) on shares of GeneDx in a research note on Tuesday, February 24th. Guggenheim lowered their price objective on GeneDx from $170.00 to $100.00 and set a "buy" rating for the company in a research note on Monday. Wells Fargo & Company raised GeneDx from an "equal weight" rating to an "overweight" rating and set a $155.00 target price on the stock in a research report on Monday, February 9th. BTIG Research reduced their target price on GeneDx from $200.00 to $170.00 and set a "buy" rating for the company in a research note on Tuesday, February 24th. Finally, Wall Street Zen downgraded shares of GeneDx from a "buy" rating to a "hold" rating in a research report on Sunday, February 8th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $140.71.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx's laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.